Protein C News and Research

RSS

Study identifies NCOA3 as a novel therapeutic target for melanoma

For the first time, activation of nuclear receptor coactivator 3 (NCOA3) has been shown to promote the development of melanoma through regulation of ultraviolet radiation (UVR) sensitivity, cell cycle progression and circumvention of the DNA damage response.

25 Mar 2021

Drugging RNA synthesis in SARS-CoV-2 as novel therapeutic avenue

In a new study, the role of a coronavirus-specific protein domain in SARS-CoV-2 viral synthesis initiation is investigated, and potential therapeutic solutions have been explored.

25 Mar 2021

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

A team of scientists from the USA and Canada recently characterized the cross-neutralizing potency of anti-SARS-CoV-2 antibodies isolated from COVID-19 patients. The findings reveal that some of the isolated antibodies targeting the spike RBD and the S2 subunit are capable of cross-neutralizing other members of the human beta-coronavirus family.

25 Mar 2021

$Researchers move one step closer to preventing limb deformities from childhood fractures$

Researchers move one step closer to preventing limb deformities from childhood fractures

Orthopedic researchers are one step closer to preventing life-long arm and leg deformities from childhood fractures that do not heal properly.

25 Mar 2021

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

The scientific consensus is that safe and highly effective vaccines are required to end the ongoing pandemic of coronavirus disease 2019 COVID-19, caused by SARS-CoV-2. A new study describes a new vaccine that presents two viral antigens to the human immune system, in order to elicit a more efficacious response.

25 Mar 2021

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

A new study, which was released on the bioRxiv* preprint server, shows the differential effect that a standard vaccine protocol may have on individuals, based on their history of prior infection with the virus.

25 Mar 2021

Researchers examine SARS-CoV-2 RNA interactome

A new study focuses on the identification of RNA-binding protein by mass spectrometry (ChIRP-M/S) approach. This study develops a global map that contains the complete set of host proteins that involve the SARS-CoV-2 genome during infection. This study has successfully identified new SARS-CoV-2 host dependency factors by merging proteomics data with gene silencing experiments. Such a discovery has paved new roads to develop more antiviral therapies.

25 Mar 2021

Scientists produce high-resolution 3D image of sarcomere using electron cryo-tomography

Scientists have produced the first high-resolution 3D image of the sarcomere, the basic contractile unit of skeletal and heart muscle cells, by using electron cryo-tomography (cryo-ET).

25 Mar 2021

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Dr. Hans Maric has received one of the German Research Foundation's highly prestigious Emmy Noether awards, worth around 1.7 million euros.

25 Mar 2021

Alzheimer’s symptoms linked to COVID-induced brain injury

New research shows further evidence between COVID-19 infection and the development of long-term neurological symptoms. The findings found COVID-induced neuroinflammation and microvascular injury contributed to dementia-like symptoms. However, they also found evidence indicating a low possibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly invading the brain.

24 Mar 2021

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Researchers from Finland, to expand on these studies, tested some of these drugs against the new SARS-CoV-2 variants. The study is published on the preprint server bioRxiv.

24 Mar 2021

Study finds rapid spread of B.1.1.220 variant with E484K mutation in New York

New research led by Patrick McGann from Walter Reed Army Institute of Research found the first cases of the B.1.1.220 variant with an E484K mutation on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Their results suggest the variant recently emerged as B.1.1.220 was not found in New York before December 2020. Still, it quickly made up 25% of coronavirus strains in late January and early February.

24 Mar 2021

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

A recent study from France showed that the UK variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – also known as B.1.1.7 variant – can replicate much more efficiently in a reconstituted human bronchial epithelium, which may explain why it spreads so rapidly in the human population. The study is currently freely available on the bioRxiv preprint server.

24 Mar 2021

Researchers characterize a potential therapeutic target to weaken COVID-19

When invaded by a virus, our body cells launch an alert to neighboring cells to increase their antiviral defenses to prevent the infection from spreading.

24 Mar 2021

New compound may provide a basis for drug development against COVID-19

SARS-CoV-2, the virus responsible for the COVID-19 pandemic, arrived one year ago and turned our lives upside-down.

24 Mar 2021

Researchers discover a novel marker of adult human neural stem cells

The mammalian center for learning and memory, hippocampus, has a remarkable capacity to generate new neurons throughout life. Newborn neurons are produced by neural stem cells (NSCs) and they are crucial for forming neural circuits required for learning and memory, and mood control.

24 Mar 2021

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

Acriflavine is traditionally employed as a topical antiseptic, though has more recently been implicated as an antiviral agent at low doses, potentially by stimulating the production of interferon. In a new study recently uploaded to the bioRxiv* preprint server, the application of the drug to SARS-CoV-2 infection is investigated, demonstrating a broad activity towards a range of other betacoronaviruses.

24 Mar 2021

Protein C News and Research

Study identifies NCOA3 as a novel therapeutic target for melanoma

Drugging RNA synthesis in SARS-CoV-2 as novel therapeutic avenue

Identification of specific anti-SARS-CoV-2 antibodies with cross-neutralization potency

Researchers move one step closer to preventing limb deformities from childhood fractures

Dual-antigen COVID-19 vaccine elicits humoral and cellular immune responses in mice

Could an mRNA vaccine second dose reduce cellular immunity in previously infected individuals?

Researchers examine SARS-CoV-2 RNA interactome

Scientists produce high-resolution 3D image of sarcomere using electron cryo-tomography

Researcher to use new approach to explore brain proteins and their potential to cure mental diseases

Alzheimer’s symptoms linked to COVID-induced brain injury

Fluoxetine (Prozac) performs strongly in vitro against SARS-CoV-2 (including mutants)

Study finds rapid spread of B.1.1.220 variant with E484K mutation in New York

Increased replicative fitness of SARS-CoV-2 UK strain in human bronchial cells

Researchers characterize a potential therapeutic target to weaken COVID-19

New compound may provide a basis for drug development against COVID-19

Researchers discover a novel marker of adult human neural stem cells

Researchers examine acriflavine's antiviral potential against SARS-CoV-2

SARS-CoV-2 can cause persistent dendritic cell deficiencies

Reduced mRNA COVID-19 vaccine response in nursing home residents

Pangolin coronavirus sheds light on UK SARS-CoV-2 variant's evolutionary trajectory

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News